Loading...
Loading...
Endo Health Solutions Inc.
announced today that its subsidiary, Endo Pharmaceuticals Inc.,
has supplemented its OPANA^® ER Citizen Petition to include emerging safety
data that demonstrate that the introduction in the first quarter of 2012 of
the reformulated OPANA ER (oxymorphone HCl) designed to be crush-resistant, is
reducing rates of abuse.
Comparisons of abuse rates for OPANA ER, from the third quarter of 2011
through the third quarter of 2012, demonstrate that the reported rate of abuse
of the reformulated OPANA ER was reduced by 59 percent, based on the total
number of prescriptions dispensed, versus the rate observed for the
non-tamper-resistant formulation of OPANA ER, which is no longer being
manufactured by the company.
The initial safety information is based on data collected by two national
programs. The first includes surveillance of substance abusers (through the
third quarter of 2012) and the second collects data from U.S. Poison Control
Centers.
The full data through the third quarter of 2012 strongly suggest that the
reformulation of OPANA ER designed to be crush-resistant is having the desired
effect on the rates and routes of abuse of the product and this new
information supports Endo's position that the original non-crush-resistant
formulation was discontinued from the market for reasons of safety.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in